Effect of albumin administration on outcomes in hypoalbuminemic patients hospitalized with community-acquired pneumonia (ALBUCAP): a prospective, randomized, phase III clinical controlled trial—a trial protocol

Background Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in h...

Full description

Saved in:
Bibliographic Details
Published inCurrent controlled trials in cardiovascular medicine Vol. 21; no. 1; pp. 727 - 8
Main Authors Rombauts, Alexander, Abelenda-Alonso, Gabriela, Simonetti, Antonella Francesca, Verdejo, Guillermo, Meije, Yolanda, Ortega, Lucia, Clemente, Mercedes, Niubó, Jordi, Ruiz, Yolanda, Gudiol, Carlota, Tebé, Cristian, Videla, Sebastian, Carratalà, Jordi
Format Journal Article
LanguageEnglish
Published London BioMed Central 20.08.2020
BioMed Central Ltd
BMC
Subjects
Albumin
Antibiotics
Antigens
Ascites
Bacterial infections
Biomedicine
Care and treatment
Clinical trials
Community-acquired infections
Community-acquired pneumonia
Health aspects
Health Sciences
Hospitalization
Hypoxia
Inflammation
Liver cirrhosis
Medicine
Medicine & Public Health
Mortality
Nosocomial infections
Patient outcomes
Patients
Pneumonia
Protein deficiency
Randomized controlled trial
Sepsis
Statistics for Life Sciences
Study Protocol
Testing
Spain
Albumin
Inflammation
Community-acquired pneumonia
Randomized controlled trial
Online AccessGet full text
ISSN1745-6215
1745-6215
DOI10.1186/s13063-020-04627-1

Cover

Abstract Background Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone. Methods This is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic (≤ 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone. Discussion If this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP. Trial registration European Clinical Trials Database (EudraCT) 2018-003117-18 . Registered on 12 April 2019. ClinicalTrials.gov NCT04071041 . Registered on 27 August 2019
AbstractList Abstract Background Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone. Methods This is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic (≤ 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone. Discussion If this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP. Trial registration European Clinical Trials Database (EudraCT) 2018-003117-18 . Registered on 12 April 2019. ClinicalTrials.gov NCT04071041 . Registered on 27 August 2019
Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone.BACKGROUNDCommunity-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone.This is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic (≤ 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone.METHODSThis is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic (≤ 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone.If this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP.DISCUSSIONIf this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP.European Clinical Trials Database (EudraCT) 2018-003117-18 . Registered on 12 April 2019. ClinicalTrials.gov NCT04071041 . Registered on 27 August 2019.TRIAL REGISTRATIONEuropean Clinical Trials Database (EudraCT) 2018-003117-18 . Registered on 12 April 2019. ClinicalTrials.gov NCT04071041 . Registered on 27 August 2019.
Background Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone. Methods This is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic ([less than or equai to] 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone. Discussion If this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP. Trial registration European Clinical Trials Database (EudraCT) 2018-003117-18. Registered on 12 April 2019. ClinicalTrials.gov NCT04071041. Registered on 27 August 2019 Keywords: Community-acquired pneumonia, Albumin, Inflammation, Randomized controlled trial
BackgroundCommunity-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone.MethodsThis is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic (≤ 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone.DiscussionIf this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP.Trial registrationEuropean Clinical Trials Database (EudraCT) 2018-003117-18. Registered on 12 April 2019. ClinicalTrials.gov NCT04071041. Registered on 27 August 2019
Background Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone. Methods This is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic (≤ 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone. Discussion If this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP. Trial registration European Clinical Trials Database (EudraCT) 2018-003117-18 . Registered on 12 April 2019. ClinicalTrials.gov NCT04071041 . Registered on 27 August 2019
Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone. This is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic ([less than or equai to] 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone. If this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP.
ArticleNumber 727
Audience Academic
Author Rombauts, Alexander
Ortega, Lucia
Clemente, Mercedes
Ruiz, Yolanda
Meije, Yolanda
Videla, Sebastian
Abelenda-Alonso, Gabriela
Niubó, Jordi
Gudiol, Carlota
Carratalà, Jordi
Verdejo, Guillermo
Simonetti, Antonella Francesca
Tebé, Cristian
Author_xml – sequence: 1
  givenname: Alexander
  surname: Rombauts
  fullname: Rombauts, Alexander
  email: alexander.rombauts@gmail.com
  organization: Department of Infectious Disease, Hospital Universitari de Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL)
– sequence: 2
  givenname: Gabriela
  surname: Abelenda-Alonso
  fullname: Abelenda-Alonso, Gabriela
  organization: Department of Infectious Disease, Hospital Universitari de Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL)
– sequence: 3
  givenname: Antonella Francesca
  surname: Simonetti
  fullname: Simonetti, Antonella Francesca
  organization: Department of Internal Medicine, Hospital Residència Sant Camil-Consorci Sanitari del Garraf
– sequence: 4
  givenname: Guillermo
  surname: Verdejo
  fullname: Verdejo, Guillermo
  organization: Department of Internal Medicine, Hospital Residència Sant Camil-Consorci Sanitari del Garraf
– sequence: 5
  givenname: Yolanda
  surname: Meije
  fullname: Meije, Yolanda
  organization: Infectious Diseases Unit - Internal Medicine Department, Hospital de Barcelona, Societat Cooperativa d’Instal·lacions Assistencials Sanitàries (SCIAS)
– sequence: 6
  givenname: Lucia
  surname: Ortega
  fullname: Ortega, Lucia
  organization: Infectious Diseases Unit - Internal Medicine Department, Hospital de Barcelona, Societat Cooperativa d’Instal·lacions Assistencials Sanitàries (SCIAS)
– sequence: 7
  givenname: Mercedes
  surname: Clemente
  fullname: Clemente, Mercedes
  organization: Infectious Diseases Unit - Internal Medicine Department, Hospital de Barcelona, Societat Cooperativa d’Instal·lacions Assistencials Sanitàries (SCIAS)
– sequence: 8
  givenname: Jordi
  surname: Niubó
  fullname: Niubó, Jordi
  organization: Department of Microbiology, Hospital Universitari de Bellvitge
– sequence: 9
  givenname: Yolanda
  surname: Ruiz
  fullname: Ruiz, Yolanda
  organization: Department of Pneumology, Hospital Universitari de Bellvitge
– sequence: 10
  givenname: Carlota
  surname: Gudiol
  fullname: Gudiol, Carlota
  organization: Department of Infectious Disease, Hospital Universitari de Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III
– sequence: 11
  givenname: Cristian
  surname: Tebé
  fullname: Tebé, Cristian
  organization: Biostatistic Unit at IDIBELL
– sequence: 12
  givenname: Sebastian
  surname: Videla
  fullname: Videla, Sebastian
  organization: Department of Clinical Pharmacology, Hospital Universitari de Bellvitge
– sequence: 13
  givenname: Jordi
  surname: Carratalà
  fullname: Carratalà, Jordi
  organization: Department of Infectious Disease, Hospital Universitari de Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III
BookMark eNp9ks1u1DAUhSNURH_gBVhZYlOkpthx4jgskIaqwEiVYEHXluPYM64cO7WdorLiIXg0noAn4U6nqLRCVaLEuT7ni3199osdH7wuipcEHxPC2ZtEKGa0xBUucc2qtiRPij3S1k3JKtLs_DPeLfZTusC4ph2tnxW7tOKkg4-94tepMVplFAySrp9H65Ec4GlTjjLb4NHmnrMKo04IZtfXU7hV6tEqNIFK-5zQOqTJZunsdz2gbzavEXjG2dt8XUp1OdsI9cnreQzeSnS4OHt_frL48votkmiKYIZl2Ct9hKL0Qxg3mCM0rWXSaLlcIuVgUUo6oPocg3NAy9FK9_vHT7kdbTA5qOCeF0-NdEm_uH0fFOcfTr-efCrPPn9cnizOStXwOpe8VcYY3vGWcqwZqY3mA62qpu4p0wOutWy7jjMsMTfEMKl0z5pG8Z51lCtND4rlljsEeSGmaEcZr0WQVtwUQlwJGbNVTguDe62ZNj0Z2rrHig-srdumbTrMOyIlsN5tWdPcj3pQ0NMo3T3o_Rlv12IVrkRbU961HACHt4AYLmedshhtUto56XWYk6hqymjHOwjBQfHqgfQizNFDqwQEo6JVW7HqTrWSsAHrTYD_qg1ULBitoQVV04Dq-D8quIZNPCCwxkL9noFvDQoOPUVthILYbKIGRusEwWKTbrFNt4B0i5t0CwLW6oH1b3seNdGtKYHYr3S82-wjrj_6wBJ_
CitedBy_id crossref_primary_10_1039_D4AN00881B
crossref_primary_10_1016_j_eclinm_2024_102898
crossref_primary_10_1016_j_genhosppsych_2023_11_013
crossref_primary_10_3390_ijms22094496
Cites_doi 10.1161/CIRCULATIONAHA.111.040766
10.1007/s001340100914
10.1097/01.SLA.0000055547.93484.87
10.1111/eci.12865
10.1001/jama.279.18.1452
10.2165/11539220-000000000-00000
10.1186/s13054-014-0702-y
10.1186/2110-5820-3-4
10.1016/j.jcrc.2010.10.007
10.1007/s00134-017-4683-6
10.1001/archinte.167.15.1655
10.1177/0885066616685300
10.1016/j.biologicals.2016.04.002
10.1186/s12913-018-3529-4
10.1056/NEJMoa040232
10.1016/j.jinf.2012.09.003
10.2147/IJGM.S102819
10.1186/s13054-016-1536-6
10.1164/rccm.201908-1581ST
10.1097/CCM.0b013e318211ff6e
10.1016/j.jiac.2018.03.006
10.1136/bmj.g4561
10.1177/09680519020080020501
10.1186/cc13812
10.1042/cs1030525
10.1097/MLR.0b013e31822efb09
10.1186/cc13187
10.1007/s00134-015-3794-1
10.1186/s12931-018-0781-4
10.1111/j.1423-0410.2011.01475.x
10.1111/liv.13968
10.1080/17512433.2018.1412827
10.1097/01.CCM.0000260242.77637.57
10.1016/j.jinf.2019.04.006
10.1016/S0140-6736(17)32152-9
10.1371/journal.pone.0114666
10.1038/nm.3516
10.3201/eid2209.150680
10.1136/thx.2009.129502
10.1093/cid/cix647
10.1097/CCM.0b013e3181ffe217
10.1016/j.mam.2011.12.002
10.1056/NEJMoa1305727
10.1016/j.jinf.2012.12.007
10.1016/S0140-6736(18)30840-7
10.1164/rccm.201501-0140OC
10.4187/respcare.05719
10.1016/0026-0495(94)90117-1
ContentType Journal Article
Copyright The Author(s) 2020
COPYRIGHT 2020 BioMed Central Ltd.
The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2020
– notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
3V.
7RV
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13063-020-04627-1
DatabaseName Springer Nature OA Free Journals
CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database (Proquest)
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Medical Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database (Proquest)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1745-6215
EndPage 8
ExternalDocumentID oai_doaj_org_article_f0bee6efb1d74b0c8d674757590891aa
PMC7438978
A634938255
10_1186_s13063_020_04627_1
GeographicLocations Spain
GeographicLocations_xml – name: Spain
GrantInformation_xml – fundername: Instituto de Salud Carlos III
  grantid: PI17/01332
  funderid: http://dx.doi.org/10.13039/501100004587
– fundername: ;
  grantid: PI17/01332
GroupedDBID ---
0R~
123
2-G
29Q
2WC
53G
5VS
6PF
7RV
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACUHS
ADBBV
ADRAZ
ADUKV
AEGXH
AENEX
AFKRA
AFPKN
AHBYD
AHYZX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
NAPCQ
O5R
O5S
OVT
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
U2A
UKHRP
WOQ
WOW
~8M
AAYXX
ALIPV
CITATION
PMFND
3V.
5GY
7XB
8FK
AHMBA
AZQEC
COVID
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
XSB
7X8
5PM
ID FETCH-LOGICAL-c584t-87cfff8987380e614fe8d32254b36ed04ea799860a08f1f6aceb655c8b6938ce3
IEDL.DBID DOA
ISSN 1745-6215
IngestDate Wed Aug 27 01:24:37 EDT 2025
Thu Aug 21 18:25:57 EDT 2025
Thu Sep 04 21:05:06 EDT 2025
Fri Jul 25 10:14:22 EDT 2025
Tue Jun 17 21:28:18 EDT 2025
Tue Jun 10 20:33:26 EDT 2025
Thu Apr 24 22:57:24 EDT 2025
Tue Jul 01 04:00:47 EDT 2025
Sat Sep 06 07:26:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Albumin
Inflammation
Community-acquired pneumonia
Randomized controlled trial
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c584t-87cfff8987380e614fe8d32254b36ed04ea799860a08f1f6aceb655c8b6938ce3
Notes ObjectType-Article-1
ObjectType-Evidence Based Healthcare-3
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
OpenAccessLink https://doaj.org/article/f0bee6efb1d74b0c8d674757590891aa
PMID 32819439
PQID 2812327262
PQPubID 44365
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_f0bee6efb1d74b0c8d674757590891aa
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7438978
proquest_miscellaneous_2436398904
proquest_journals_2812327262
gale_infotracmisc_A634938255
gale_infotracacademiconefile_A634938255
crossref_citationtrail_10_1186_s13063_020_04627_1
crossref_primary_10_1186_s13063_020_04627_1
springer_journals_10_1186_s13063_020_04627_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-08-20
PublicationDateYYYYMMDD 2020-08-20
PublicationDate_xml – month: 08
  year: 2020
  text: 2020-08-20
  day: 20
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Current controlled trials in cardiovascular medicine
PublicationTitleAbbrev Trials
PublicationYear 2020
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References PE Ballmer (4627_CR26) 1994; 43
S Tong (4627_CR12) 2018; 18
WW Siljan (4627_CR17) 2018; 48
4627_CR32
4627_CR33
4627_CR30
4627_CR36
4627_CR37
4627_CR34
4627_CR35
A Patel (4627_CR44) 2014; 349
4627_CR38
4627_CR40
4627_CR43
A Komáromi (4627_CR28) 2016; 20
4627_CR41
4627_CR42
4627_CR47
C Uhlig (4627_CR48) 2014; 18
4627_CR46
M Ulldemolins (4627_CR31) 2011; 50
4627_CR49
L Jiang (4627_CR45) 2014; 9
T Welte (4627_CR11) 2012; 67
M Di Pascoli (4627_CR39) 2019; 39
4627_CR10
4627_CR14
4627_CR15
4627_CR13
4627_CR18
4627_CR19
4627_CR16
4627_CR9
4627_CR7
DT Eurich (4627_CR8) 2015; 192
4627_CR21
4627_CR22
4627_CR20
4627_CR2
4627_CR25
4627_CR1
4627_CR23
4627_CR24
4627_CR6
4627_CR29
4627_CR5
4627_CR4
4627_CR27
4627_CR3
References_xml – ident: 4627_CR10
  doi: 10.1161/CIRCULATIONAHA.111.040766
– ident: 4627_CR27
  doi: 10.1007/s001340100914
– ident: 4627_CR18
  doi: 10.1097/01.SLA.0000055547.93484.87
– volume: 48
  year: 2018
  ident: 4627_CR17
  publication-title: Eur J Clin Investig
  doi: 10.1111/eci.12865
– ident: 4627_CR14
  doi: 10.1001/jama.279.18.1452
– volume: 50
  start-page: 99
  year: 2011
  ident: 4627_CR31
  publication-title: Clin Pharmacokinet
  doi: 10.2165/11539220-000000000-00000
– ident: 4627_CR43
  doi: 10.1186/s13054-014-0702-y
– ident: 4627_CR32
  doi: 10.1186/2110-5820-3-4
– ident: 4627_CR23
  doi: 10.1016/j.jcrc.2010.10.007
– ident: 4627_CR49
  doi: 10.1007/s00134-017-4683-6
– ident: 4627_CR15
  doi: 10.1001/archinte.167.15.1655
– ident: 4627_CR19
  doi: 10.1177/0885066616685300
– ident: 4627_CR35
  doi: 10.1016/j.biologicals.2016.04.002
– volume: 18
  start-page: 715
  year: 2018
  ident: 4627_CR12
  publication-title: BMC Health Serv Res
  doi: 10.1186/s12913-018-3529-4
– ident: 4627_CR41
  doi: 10.1056/NEJMoa040232
– ident: 4627_CR9
  doi: 10.1016/j.jinf.2012.09.003
– ident: 4627_CR25
  doi: 10.2147/IJGM.S102819
– volume: 20
  start-page: 370
  year: 2016
  ident: 4627_CR28
  publication-title: Crit Care
  doi: 10.1186/s13054-016-1536-6
– ident: 4627_CR1
  doi: 10.1164/rccm.201908-1581ST
– ident: 4627_CR34
  doi: 10.1097/CCM.0b013e318211ff6e
– ident: 4627_CR20
  doi: 10.1016/j.jiac.2018.03.006
– volume: 349
  start-page: g4561
  year: 2014
  ident: 4627_CR44
  publication-title: BMJ.
  doi: 10.1136/bmj.g4561
– ident: 4627_CR33
  doi: 10.1177/09680519020080020501
– ident: 4627_CR7
  doi: 10.1186/cc13812
– ident: 4627_CR29
  doi: 10.1042/cs1030525
– ident: 4627_CR13
  doi: 10.1097/MLR.0b013e31822efb09
– volume: 18
  start-page: R10
  year: 2014
  ident: 4627_CR48
  publication-title: Crit Care
  doi: 10.1186/cc13187
– ident: 4627_CR46
  doi: 10.1007/s00134-015-3794-1
– ident: 4627_CR6
  doi: 10.1186/s12931-018-0781-4
– ident: 4627_CR36
  doi: 10.1111/j.1423-0410.2011.01475.x
– volume: 39
  start-page: 98
  year: 2019
  ident: 4627_CR39
  publication-title: Liver Int
  doi: 10.1111/liv.13968
– ident: 4627_CR3
– ident: 4627_CR30
  doi: 10.1080/17512433.2018.1412827
– ident: 4627_CR40
  doi: 10.1097/01.CCM.0000260242.77637.57
– ident: 4627_CR16
  doi: 10.1016/j.jinf.2019.04.006
– ident: 4627_CR4
  doi: 10.1016/S0140-6736(17)32152-9
– volume: 9
  year: 2014
  ident: 4627_CR45
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0114666
– ident: 4627_CR37
  doi: 10.1038/nm.3516
– ident: 4627_CR5
  doi: 10.3201/eid2209.150680
– volume: 67
  start-page: 71
  year: 2012
  ident: 4627_CR11
  publication-title: Thorax.
  doi: 10.1136/thx.2009.129502
– ident: 4627_CR2
  doi: 10.1093/cid/cix647
– ident: 4627_CR47
  doi: 10.1097/CCM.0b013e3181ffe217
– ident: 4627_CR24
  doi: 10.1016/j.mam.2011.12.002
– ident: 4627_CR42
  doi: 10.1056/NEJMoa1305727
– ident: 4627_CR22
  doi: 10.1016/j.jinf.2012.12.007
– ident: 4627_CR38
  doi: 10.1016/S0140-6736(18)30840-7
– volume: 192
  start-page: 597
  year: 2015
  ident: 4627_CR8
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201501-0140OC
– ident: 4627_CR21
  doi: 10.4187/respcare.05719
– volume: 43
  start-page: 697
  year: 1994
  ident: 4627_CR26
  publication-title: Metabolism.
  doi: 10.1016/0026-0495(94)90117-1
SSID ssj0043934
ssj0017864
Score 2.2571628
Snippet Background Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it...
Background Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it...
Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains...
BackgroundCommunity-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it...
Abstract Background Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes....
SourceID doaj
pubmedcentral
proquest
gale
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 727
SubjectTerms Albumin
Antibiotics
Antigens
Ascites
Bacterial infections
Biomedicine
Care and treatment
Clinical trials
Community-acquired infections
Community-acquired pneumonia
Health aspects
Health Sciences
Hospitalization
Hypoxia
Inflammation
Liver cirrhosis
Medicine
Medicine & Public Health
Mortality
Nosocomial infections
Patient outcomes
Patients
Pneumonia
Protein deficiency
Randomized controlled trial
Sepsis
Statistics for Life Sciences
Study Protocol
Testing
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1db9QwLIJNQrwgPkXZQEFCAsRVS6-5NOUF3dCmHWLThJi0tyhNE-6k0d7W3sN44kfw0_gF_BLsNL2pTEy6h6pxcnXs2E7s2IS8YnqSpJonaLmxmFshY83yLDY5d6XmTGc-GPPwSByc8E-nk9Nw4NaEsMpeJnpBXdYGz8h3xhKVfzYW4w_L8xirRqF3NZTQuE02QQRL4PPN3b2j4y9rP0ImBe-vykix04DE9n5LH9I4zuJkoI581v7rsvl6vOQ_TlOvi_bvk3vBiKTTjuoPyC1bPSR3DoOb_BH53eUkprWjPvx4UVE9SJJL8bdqAXPbUGidXy7rAInB8jRkW23oPJQVWfywJcUzW2q6GyXtZawNRhHD-2VlVzA9C03fTD-D0Ts9fvueagqI9fc4RxRUYll_x2FGdDkH1Ulnsxnt72XSEDF_BqP5OiJ_fv7S3RMO09bAro_Jyf7e148HcSjfEBuwalqQs8Y5J3OZpZJZMAOclSXKD16kwpaMW53BZk8wzaRLnNDGFmIyMbIQeSqNTZ-Qjaqu7FNCUyA9dLOJ0ZJbWcjUoUuTFSItSniISNJTUZmQ2xxLbJwpv8eRQnWUV0B55Smvkoi8W_dZdpk9boTeReZYQ2JWbv-ivvimwiJXjhXWCuuKpMx4wYwsBezWsAQqk3midUReI2splB3weUaHKxCAJGbhUlORckAddnkR2R5Awpo3w-aeOVWQOY26WiERebluxp4YR1fZegUwPAWTVOaMRyQbMPUAs2FLtZj7vONgbMo8g8ke9ex_9ef_n7lnN3_rFrk79usRBfY22WgvVvY52Hlt8SIs5r_JaVWY
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3bihMxNCwriC_iFUdXiSCo2NFMk2YygkgVl61Y8cGFfQuZTLIt1JnaTsH65Ef4aX6BX-I5mZnKuKtPQh-GyUnaJOfacyPkATOjhBuRoObGYuGkig3L0thmwhdGMJOGYMzpe3l0LN6ejE72SNfuqD3A9bmmHfaTOl4tnn75vH0JBP8iELySz9bAh4M3MgQqDtMYrKELIJkkGmNTsfMqgOzlokucOXdeTziFGv5nOfXZ6Mk_XKhBMh1eIZdblZKOGxy4SvZceY1cnLZO8-vkR1OhmFaehmDkeUlNr2Quxc-mBtxzawqjs-2yaiExdJ62tVfXdNY2GZl_dQXFf3CpbfJL6m1sLMYUw_tl6TaA23NDH43fgQo8_vD4OTUUNtZldQ4oCMii-oTLDOhyBoKUTiYT2mVp0jZ-fgGrha4iP799N80TLlNXgLw3yPHhm4-vj-K2mUNsQcepgeta773KVMoVc6AUeKcK5CYi59IVTDiTguknmWHKJ14a63I5GlmVy4wr6_hNsl9WpbtFKActEKa5xBolnMoV9-jgZLnkeQEPEUm6W9S2rXSODTcWOlg8Surm5jXcvA43r5OIPNnNWTZ1Pv4J_QqRYweJNbrDi2p1qluS157lzknn86RIRc6sKiTYbtgQlaksMSYiDxG1NOI2_Dxr2oQI2CTW5NJjyQVsHWy-iBz0IIED2P5wh5y6IyA9VKgsp0M5jMj93TDOxKi60lUbgBEcFFSVMRGRtIfUvZ31R8r5LFQhB9VTZSkc9qBD_99f_veTu_0_Tu4OuTQMVItM_oDs16uNuwu6YZ3fCwT_CwuuZK8
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3bitQwNMgK4ot4xeoqEQQVp5hOMmnq27i47IgrPriwbyFJE2ZgbQen87A--RF-ml_gl3hOmo7WVUHoQ2lOMk3PybnMuRHymJlZwY0oUHNjufBS5YZVZe4qEWojmCljMObxO3l0It6czk5TmRzMhfnVf18o-WIDPDZ6GmMQ4rTMwdK5DMvL6JiVBwPXBbnKxZAU88d5I8ET6_Nf5MIXIyN_c49GqXN4nVxL6iKd9_i9QS755ia5cpwc4rfIt776MG0DjYHGq4aaUTlcite2A7ryGwqjy_N1myAxLJ6muqobukwNRFaffU3x31nq-tyR7jw3DuOF4fm68Vug25WhT-dvQb2dv3_2khoKGxsyNicUhF_dfsRlJnS9BCFJF4sFHTIwaYqNP4PVYseQ71--mv4Ol-laIMzb5OTw9YeDozw1asgd6C8dcFQXQlCVKrliHgR-8KpGTiEsl75mwpsSzDrJDFOhCNI4b-Vs5pSVFVfO8ztkr2kbf5dQDhoeTPOFM0p4ZRUP6LxkVnJbw01GigGL2qUq5thM40xHa0ZJ3WNeA-Z1xLwuMvJ8N2fd1_D4J_QrJI4dJNbfjg-ALHU6zjow6730wRZ1KSxzqpZgl2GzU6aqwpiMPEHS0sgl4PWcSckOsEmst6XnkgvYOthzGdkfQcLpduPhgTh14i4bPVWoCJdTOc3Io90wzsSIuca3W4ARcEYqVTGRkXJE1KOdjUea1TJWGAe1UlUlfOzJQP4_f_zvX-7e_4HfJ1en8Xwiq94ne92nrX8AGl5nH8aj_QO8zE0H
  priority: 102
  providerName: Springer Nature
Title Effect of albumin administration on outcomes in hypoalbuminemic patients hospitalized with community-acquired pneumonia (ALBUCAP): a prospective, randomized, phase III clinical controlled trial—a trial protocol
URI https://link.springer.com/article/10.1186/s13063-020-04627-1
https://www.proquest.com/docview/2812327262
https://www.proquest.com/docview/2436398904
https://pubmed.ncbi.nlm.nih.gov/PMC7438978
https://doaj.org/article/f0bee6efb1d74b0c8d674757590891aa
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwFLZgSIgbxK8IjMpISIBoNCdxHYe7rNpYKzpNQKXeWY5jq5W2pKLpxbjiIXg0noAn4dhxCmECbpCqNPJfY_vLOZ_r43MQek7kKEokjSxzIyHVjIeSZGmoMmpKSYlMnTHm7JSdzOl0MVr8EurL2oS17oHbgTswpNCaaVNEZUoLonjJgAHbsJKEZ5F01IhkpFtMtTIYtGxCuyMynB1sQFK7_UpnyhinYdRTQ85b_1WZfNVO8rfNUqeDju-g25484rx96Lvomq7uoZszvz1-H31rfRHj2mBndryqsOw5x8X2s20AZXqDIXd5ua59SWskj72X1Q1e-nAiq8-6xPa_WqzakyTNZSiVtR6G9HWlt4DilcQv83dAdvOzV2-wxNCx7vzmEIMqLOsL28wQr5egMvFkMsHdeUzsLeXPoTUXP-T7l6-yvbPNNDXA9AGaHx99HJ-EPmxDqIDNNCBflTGGZzxNONGg_o3mpZUbtEiYLgnVMoVFHiOScBMZJpUu2GikeMGyhCudPER7VV3pRwgnwPegmo6U5FTzgifGbmWSgiVFCTcBirpZFMr7NLehNc6FW9twJtqZFzDzws28iAL0eldn3Xr0-GvpQwuOXUnrjdslAEaFx6j4F0YD9MJCS1iZAY-npD_6AJ203rdEzhIKXYfVXYD2eyXhXVf97A6cwsuajYi5pcVpzOIAPdtl25rWfq7S9RbK0ASoKM8IDVDaA3WvZ_2carV0_saBZPIshcEedvD_-eN_HrnH_2PknqBbsXtrrTjfR3vNp61-CiywKQboerpIB-hGnk8_TOH78Oj07D2kjtl44IQBXN8uIrjOKIfrPM5_AERNZOs
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BqdBLwgriIwwEggQDSak7iOi4RQB5tW1lYT2qS9eY7j0EojKWsrVJ74CL6Dr-EL-BLOcZJOYWJvk_IQxZfEPsfnknMj5BnTnSDSPEDJjfncCulr1o190-VZqjnTsXPGHI7E7iH_eNQ5WiO_6lgYdKusaaIj1Glh8B_5ZiiR-cehCN9Nv_pYNQqtq3UJjRIt9uzyG6hss7f9DwDf52G4s33wftevqgr4BpjtHI6_ybJMgq4dSWaBO2VWpojWPImETRm3OgYdRDDNZBZkQhubiE7HyER0I2lsBPNeIescI1pbZH1re7T_aWW3iKXgdWiOFJsz4BDOTupcKMPYDxrsz1UJOM8Lzvtn_mOkdbxv5ya5UQmttFdi2S2yZvPb5OqwMsvfIb_LHMi0yKhzd57kVDeS8lK8FnPYaTuj0DpeTouqJzrn0yq764yOqzImk-82pfiPmJoygmW-9LVBr2V4Ps3tAsAx0fRlbwBCdm__1RuqKSysjhttU2DBafEFp2nT6RhYNe33-7SOA6WVh_4JzObqlvz58VOXdzjNvIDjcZccXgpg75FWXuT2PqERoBoMs4HRkluZyChDEypLRJSkcOORoIaiMlUudSzpcaKcTiWFKiGvAPLKQV4FHnm9GjMtM4lc2HsLkWPVE7OAuwfF6WdVERWVscRaYbMkSGOeMCNTAdohllxlshto7ZEXiFoKaRV8ntFVyAUsErN-qZ6IOCwdtEqPbDR6Ao0xzeYaOVVF42bq7ER65OmqGUei315uiwX04RGIwLLLuEfiBlI3VtZsySdjl-cchFvZjWGz2zX6n738_zv34OJvfUKu7R4MB2rQH-09JNdDdzaRWWyQ1vx0YR-BjDlPHlcHm5Ljy6YlfwH455Kt
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BqdNPGCuIrAACOBALGoTuI6DhJCHVu1sq2qEJP25jmOQyuNpKypUHniI_gavoMv4Es4dpxOYWJvk_IQxZfEPsfnknND6BmRvSCSNDCSG_GpZtyXJIl9ldA8k5TI2DpjHo7Y3hH9cNw7XkO_mlgY41bZ0ERLqLNSmX_k3ZAb5h-HLOzmzi1ivDN4N_vqmwpSxtLalNOoUWRfL7-B-jZ_O9wBWD8Pw8Hup_d7vqsw4CtgvBWQApXnOQe9O-JEA6fKNc8MitM0YjojVMsY9BFGJOF5kDOpdMp6PcVTlkRc6QjmvYbWY-CKtIPWt3dH448rG0bMGW3CdDjrzoFbWJupdacMYz9osUJbMeAiX7joq_mPwdbywcFNdMMJsLhfY9wttKaL22jj0Jno76DfdT5kXObYuj5PCyxbCXqxuRYV7LqeY2idLGel62kc9bHL9DrHE1fSZPpdZ9j8L8aqjmaplr5UxoMZns8KvQBwTCV-2T8Agbs_fvUGSwwLa2JItzCw46z8YqbZwrMJsG08HA5xExOKnbf-Kcxma5j8-fFT1ndmmqqEo3IXHV0JYO-hTlEW-j7CEaAdDNOBkpxqnvIoN-ZUkrIozeDGQ0EDRaFcXnVT3uNUWP2KM1FDXgDkhYW8CDz0ejVmVmcVubT3tkGOVU-TEdw-KM8-C0dgRE5SrZnO0yCLaUoUzxhoiqb8KuFJIKWHXhjUEoZuwecp6cIvYJEmA5jos4jC0kHD9NBmqyfQG9VubpBTOHo3F-en00NPV81mpPHhK3S5gD40AnGYJ4R6KG4hdWtl7ZZiOrE5z0HQ5UkMm73VoP_5y_-_cw8u_9YnaANoiDgYjvYfouuhPZqGb2yiTnW20I9A3KzSx-5cY3Ry1aTkL4cXltk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+albumin+administration+on+outcomes+in+hypoalbuminemic+patients+hospitalized+with+community-acquired+pneumonia+%28ALBUCAP%29%3A+a+prospective%2C+randomized%2C+phase+III+clinical+controlled+trial%E2%80%94a+trial+protocol&rft.jtitle=Trials&rft.au=Alexander+Rombauts&rft.au=Gabriela+Abelenda-Alonso&rft.au=Antonella+Francesca+Simonetti&rft.au=Guillermo+Verdejo&rft.date=2020-08-20&rft.pub=BMC&rft.eissn=1745-6215&rft.volume=21&rft.issue=1&rft.spage=1&rft.epage=8&rft_id=info:doi/10.1186%2Fs13063-020-04627-1&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_f0bee6efb1d74b0c8d674757590891aa
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon